Drug Profile

CNTY 813

Alternative Names: CNTY-813

Latest Information Update: 19 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Century Therapeutics
Class Cell therapies; Gene therapies; Induced pluripotent stem cell therapies
Mechanism of Action Pancreatic beta cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Type 1 diabetes mellitus

Most Recent Events

12 Aug 2026 Century Therapeutics completes a pre-IND meeting with the US FDA for CNTY 813 in Type 1 diabetes (T1D)
08 Jun 2026 Pharmacodynamics and adverse events data from a preclinical trial in Type 1 diabetes mellitus released by Century Therapeutics
12 Mar 2026 Century Therapeutics plans to file IND application with the US FDA for Type 1 Diabetes mellitus in the fourth quarter of 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com